Home › Triple-Negative Breast Cancer › District of Columbia
Triple-Negative Breast Cancer clinical trials in District of Columbia
7 studies for Triple-Negative Breast Cancer are looking for participants at sites in District of Columbia.
Cities in District of Columbia
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Washington Hospital Center ( Site 0098), Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Georgetown University Medical Center, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149Study of XB010 in Subjects With Solid Tumors
- Georgetown University Medical Center, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT06545331I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Georgetown University Medical Center, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379CtDNA Based MRD Testing for NAC Monitoring in TNBC
- George Washington University, Washington D.C.
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.